CN1688580A - 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物 - Google Patents

作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物 Download PDF

Info

Publication number
CN1688580A
CN1688580A CNA038239779A CN03823977A CN1688580A CN 1688580 A CN1688580 A CN 1688580A CN A038239779 A CNA038239779 A CN A038239779A CN 03823977 A CN03823977 A CN 03823977A CN 1688580 A CN1688580 A CN 1688580A
Authority
CN
China
Prior art keywords
trifluoromethylpurine
methylamino
cyclopropylamino
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038239779A
Other languages
English (en)
Chinese (zh)
Inventor
刘瑞平
艾伦·T.·霍珀
阿肖克·泰希姆
汉斯－于尔根·E.·赫斯
荣雅静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of CN1688580A publication Critical patent/CN1688580A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/14—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with two methyl radicals in positions 1 and 3 and two methyl radicals in positions 7, 8, or 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA038239779A 2002-08-08 2003-08-08 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物 Pending CN1688580A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40176502P 2002-08-08 2002-08-08
US60/401,765 2002-08-08

Publications (1)

Publication Number Publication Date
CN1688580A true CN1688580A (zh) 2005-10-26

Family

ID=31715731

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038239779A Pending CN1688580A (zh) 2002-08-08 2003-08-08 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物

Country Status (9)

Country Link
US (3) US7332486B2 (https=)
EP (1) EP1529049B1 (https=)
JP (1) JP2005538134A (https=)
CN (1) CN1688580A (https=)
AT (1) ATE449099T1 (https=)
AU (1) AU2003264017B2 (https=)
CA (1) CA2494028A1 (https=)
DE (1) DE60330150D1 (https=)
WO (1) WO2004014913A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282128A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN107108517A (zh) * 2015-02-11 2017-08-29 株式会社大熊制药 钠通道阻断剂
CN108395432A (zh) * 2018-01-15 2018-08-14 吴江信凯医药科技有限公司 一种2-三氟甲基-6-氨基嘌呤的制备方法
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007134A (es) * 2001-02-08 2004-10-15 Memory Pharm Corp Trifluorometilpurinas como inhibidores de fosfodiesterasa 4.
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
ATE449099T1 (de) * 2002-08-08 2009-12-15 Memory Pharm Corp Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
WO2006123639A1 (ja) * 2005-05-18 2006-11-23 Asahi Kasei Pharma Corporation ピリミジン誘導体
EP2562168B1 (en) 2006-02-28 2014-04-16 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as pde4 inhibitors
FR2898057B1 (fr) * 2006-03-06 2008-07-04 Centre Nat Rech Scient Utilisation de composes derives de l'adenine pour le traitement de lupus
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN102282129A (zh) 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
IL316656A (en) 2016-02-09 2024-12-01 Estab Labs S A Transponders and sensors for implantable medical devices and methods of using them
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US3917583A (en) * 1972-08-04 1975-11-04 Icn Pharmaceuticals 2-Substituted cyclic AMP derivatives
AR205247A1 (es) 1973-02-07 1976-04-21 Icn Pharmaceuticals Procedimiento para preparar derivados de amp 2-substituidos
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
JP3634861B2 (ja) 1992-06-15 2005-03-30 セルテック リミテッド 選択的ホスホジエステラーゼｉｖ阻害剤としての三置換フェニル誘導体
DE4230755A1 (de) 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (https=) 1992-12-23 1995-11-21 Celltech Ltd
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
DE19702785A1 (de) 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
EP0994100B1 (en) 1997-06-24 2006-08-30 Nikken Chemicals Company, Limited 3-anilino-2-cycloalkenone derivates
WO1999024432A1 (fr) 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
DE19882892T1 (de) * 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen und Imidazopyridinen
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DE19935209A1 (de) 1999-07-27 2001-02-08 Truss Michael C Verwendung von Substanzen, die den intrazellulären Gehalt von zyklischem Adenosinmonophosphat (cAMP) erhöhen oder die Aktivität cAMP-bindender Proteine stimulieren, zur Behandlung von Erkrankungen der Harnblase
GB0011802D0 (en) 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
MXPA03007134A (es) * 2001-02-08 2004-10-15 Memory Pharm Corp Trifluorometilpurinas como inhibidores de fosfodiesterasa 4.
ATE449099T1 (de) * 2002-08-08 2009-12-15 Memory Pharm Corp Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282128A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282128B (zh) * 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN104945311A (zh) * 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN107108517A (zh) * 2015-02-11 2017-08-29 株式会社大熊制药 钠通道阻断剂
CN107108517B (zh) * 2015-02-11 2021-05-07 株式会社大熊制药 钠通道阻断剂
CN108395432A (zh) * 2018-01-15 2018-08-14 吴江信凯医药科技有限公司 一种2-三氟甲基-6-氨基嘌呤的制备方法
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
US11420970B1 (en) 2019-08-14 2022-08-23 Novartis Ag Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents
US12312353B2 (en) 2019-08-14 2025-05-27 Novartis Ag Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents

Also Published As

Publication number Publication date
AU2003264017B2 (en) 2010-05-27
US7332486B2 (en) 2008-02-19
WO2004014913A3 (en) 2004-07-29
WO2004014913A2 (en) 2004-02-19
EP1529049B1 (en) 2009-11-18
US20100004236A1 (en) 2010-01-07
DE60330150D1 (en) 2009-12-31
AU2003264017A1 (en) 2004-02-25
US20080139583A1 (en) 2008-06-12
ATE449099T1 (de) 2009-12-15
EP1529049A2 (en) 2005-05-11
US20070093510A1 (en) 2007-04-26
CA2494028A1 (en) 2004-02-19
JP2005538134A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
CN1688580A (zh) 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物
CN1501927A (zh) 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
CN1922144A (zh) 包括n－取代二芳基胺类似物在内的磷酸二酯酶4抑制剂
CN1118459C (zh) 用作α1－肾上腺素能受体拮抗剂的嘧啶二酮、嘧啶三酮、三嗪二酮衍生物
CN1809559A (zh) 作为磷酸二酯酶4抑制剂的吡唑衍生物
CN1252067C (zh) 吲哚衍生物及其作为jnk调节剂的应用
CN1498211A (zh) 用作磷酸二酯酶4抑制剂的苯胺衍生物
CN1152022C (zh) α-取代的嘧啶-硫代烷基和烷基醚化合物
CN1688545A (zh) 磷酸二酯酶4抑制剂,包括n－取代的苯胺及二苯胺类似物
CN1714081A (zh) 磷酸二酯酶4抑制剂
CN1604776A (zh) 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
CN1812973A (zh) 可用作蛋白激酶抑制剂的吲唑化合物
CN1849325A (zh) 可抑制蛋白激酶的噻唑并、噁唑并和咪唑并喹唑啉化合物
CN1745080A (zh) 1,3－二氢－咪唑稠环化合物
CN1255133A (zh) 1,5－二氢－吡唑并[3,4－d]－嘧啶酮衍生物
CN1805929A (zh) 磷酸二酯酶4抑制剂
CN1169792C (zh) 取代的乙烯基吡啶衍生物和含有它们的药物
CN1525974A (zh) 用作腺苷A2a受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用
CN1394203A (zh) 用作5－ht2a受体拮抗剂的哌啶和哌嗪衍生物
CN1922170A (zh) 新的羟基－6－杂芳基菲啶及其作为pde4
CN1835929A (zh) 作为pde9a抑制剂的6－芳氨基－5－氰基－4－嘧啶酮类化合物
CN1809349A (zh) 用于治疗神经变性疾病和炎症相关疾病的具有腺苷a2a受体结合活性和磷酸二酯酶抑制活性的5h－茚并 [1 ,2－b]吡啶的5－氧代和5－硫代衍生物
CN1668602A (zh) 作为磷酸二酯酶4抑制剂的6－氨基－1h－吲唑和4－氨基苯并呋喃化合物
CN1893944A (zh) 具有抗增殖活性的3－氰基喹啉衍生物
CN1309656A (zh) 烷硫基α－取代的嘧啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned